65,437 trials
Pre-Exposure Prophylaxis · Sexually Transmitted Diseases, Bacterial · HIV Infections
Primary: Visits With PrEP Dispensation to Female Study Participants Reporting Sexual Behaviors or STI Symptoms — 211 Visits
Parkinson Disease · Mindfulness
Primary: Recruitment of Sample: Number of Participants Recruited — 12; 12 Participants
Primary Sclerosing Cholangitis
Primary: Mean Change From Baseline in Alkaline Phosphatase in Patients With Primary Sclerosing Cholangitis — 25.6; -9.8; -0.6 International units/Liter — p=0.434
Venous Thrombosis
Primary: Efficacy Outcome - Occurrence of Symptomatic Recurrent Venous Thromboembolism — 1; 2; 2; 2 Participants
Obesity
Primary: The Incidence of Major Adverse Cardiovascular Events (MACE) Between Initiators of CONTRAVE®/MYSIMBA® or N&B and Initiators of Lorcaserin. — 26; 36; 10; 6 Events
Laparoscopic Cholecystectomy
Primary: Identification of Biliary Structures Prior to Dissection of the Hepatocystic Triangle. — 26; 20; 26; 29 Participants
Parkinsonian Signs in Older Persons
Primary: Average Gait Speed — 0.97; 0.86; 1.04; 0.95 meters per second
Tinea Pedis
Primary: Safety Evaluation Cohort 1 — 8; 0; 0; 0 Feet
Telerehabilitation · Carcinoma, Non-Small-Cell Lung · Cardiopulmonary Exercise Test
Primary: Change From Baseline in VO2 Peak (Peak Oxygen Uptake, mL/kg/Min) on the CardioPulmonary Exercise Test(CPET) After 4 Weeks Intervention — 23.67; 23.09; 19.28; 20.41…
Cardiac Rehabilitation · Health Coaching · Physical Activity
Primary: Change in Physical Activity as Measured by Steps Per Day — 1194; 554 steps per day — p=0.509
Hemiplegic Cerebral Palsy
Primary: Change in Affected Arm Movement Control — 74.9; 78.3; 83.8 percentage
Anxiety State
Primary: Change From Baseline in Heart Rate During Stressful Lethal Force Decision Making Task — 98.5; 111; 100.0; 114 bpm — p=.012
Colon Cancer · Neoadjuvant Therapy
Primary: Tumor Regression Rate of MSS/pMMR Patients — 7 Participants
Obesity-Related Malignant Neoplasm
Primary: Feasibility of a 15-week Telephone-based Weight Loss Intervention — 22; 11 Participants
Fabry Disease
Primary: Incidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and AEs (Adverse Events) Leading to Discontinuation of Study Drug — 13; 1; 0…